Biocine's gp120 HIV vaccine
Stimulated neutralizing antibodies to HIV-1, which persisted for up to six months, in healthy, uninfected volunteers, according to results of an 18-month Phase I study presented by James Kahn, University of California -- San Francisco, on June 8 at the conference on AIDS. Over a one-year period, 30 volunteers received four injections of either the vaccine combined with adjuvants, an oil and water emulsion called MF-59 or a bacterial fragment called muramyl tripeptide (MTP-PE). Twelve volunteers received either placebo or injections without the HIV vaccine antigen. All volunteers receiving the vaccine produced antibodies against HIV, and neutralizing antibodies were produced against a closely related isolate of the virus, UCSF said. "The vaccine appeared to have better staying power than some other experimental vaccines, as the antibodies persisted in the body for as much as six months after the third injection," a company release states.
You may also be interested in...
Newly released Medicare Part D data sheds light on the sales hit that branded pharmaceutical manufacturers will face when the coverage gap discount program gets under way in 2011
FDA appears headed for a showdown with clinicians and the pharmaceutical industry over the proposed new clinical trial endpoints for acute bacterial skin and skin structure infections, the guidance's approach for justifying a non-inferiority margin and proposed changes in the types of patients that should be enrolled in trials
Specialty drug maker Shire has quietly begun scouting deals with a brand-new $50 million venture fund, the latest of several in-house investment arms to launch with their parent company's pipelines, not profits, as the measure of their worth